Evaluation de la sensibilité ex vivo de Plasmodium falciparum à la Dihydroartémisinine et à la Pipéraquine à Bobo-Dioulasso, Burkina Faso
DOI:
https://doi.org/10.64707/revstss.v49i1.2332Keywords:
Plasmodium falciparum , dihydroartémisinine, pipéraquine , ex vivo susceptibilityAbstract
In Burkina Faso, malaria is a major public health problem and the leading cause of medical consultations and hospitalizations. Dihydroartemisinine-piperaquine (DHA-PPQ) is used as a first-line treatment for uncomplicated malaria. Ex vivo susceptibility testing is one of the best methods for assessing the efficacy of antimalarial compounds. The aim of this study was to test the ex vivo susceptibility of clinical isolates of Plasmodium falciparum to DHA and PPQ in the city of Bobo-Dioulasso.
A cross-sectional study was conducted at three health centers between June 2024 and January 2025. Blood samples were collected from subjects with malaria following confirmation by thick smear/blood smear, with a parasite density greater than 1%. Ex vivo sensitivity was measured after culturing the parasites, and 50% inhibitory concentrations (IC50) were determined using a standard 72-hour growth inhibition assay.
A total of 133 patients were included in the study. The growth inhibition assay for isolates had a success rate of 90.98% (121/133) for DHA and 85.71% (114/133) for PPQ. Analysis of the IC50 values revealed median values of 1.88 nM (IQR: 0.31–9.58) and 8.49 nM (IQR: 1.43–39.67) for DHA and PPQ, respectively.
The study demonstrated good sensitivity of the tested clinical isolates. Surveillance systems must be strengthened to enable earlier detection of signs of resistance.
References
Zongo I, Tinto H, Drabo KM, Rouamba N, Guiguemde TR, Ouedraogo JB. Historique de la chloroquino résistance de 2001 à 2004 au Burkina Faso : les raisons d’un changement de la politique nationale de traitement du paludisme simple : Retrospective review of chloroquine efficacy for the treatment of uncomplicated falciparum malaria in Burkina Faso over four years (2001 to 2004). Sci Santé 2007 [En ligne]. https://revuesciences techniquesburkina.org/index.php/sciences_de_la_sante/article/view/223. Consulté le 15 avr 2026 ;30(1 et 2).
Ministère de la Santé. Plan Stratégique National de Lutte contre le Paludisme 2021-2025 [En ligne]. https://pnd.finances.bf/lesdocuments/docpnd_507NMA_224.pdf. Consulté le 11 mars 2026.
Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet. 7 avr 2018;391(10128):1378‑90. doi:10.1016/S0140-6736(18)30291-5 PubMed PMID: 29606364.
Bamba S I. STUDY ON THE IN VITRO RESISTANCE OF PLASMODIUM FALCIPARUM TO ANTIMALARIAL DRUGS COUPLED WITH PFMDR1 MUTATION IN BOBODIOULASSO, BURKINA FASO. Dakar Med. 1 janv 2011 ;56 :294‑302.
Yarga S. DB. Évaluation de la sensibilité in vitro d’isolats de Plasmodium falciparum à 5 antipaludiques à Nanoro. 2013.
Somé AF, Conrad MD, Kabré Z, Fofana A, Yerbanga RS, Bazié T, et al. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrob Agents Chemother. 68(4): e01534-23. doi:10.1128/aac.01534-23 PubMed PMID: 38411062; PubMed Central PMCID: PMC10989024.
Ministère de la Santé et de l’Hygiène Publique. Lutte contre le paludisme : à Boulmiougou, les acteurs saluent une chute historique des cas et des décès en 2025. [En ligne]. https://www.sante.gov.bf/detail?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews%5D=1090&cHash=c56bd4e8d6d145c7eecf36ab6c8bcb6d. Consulté le 26 mars 2026
Severe Malaria Observatory. Le paludisme au Burkina Faso : statistiques | Severe Malaria Observatory [En ligne]. https://www.severemalaria.org/fr/pays/burkina-faso. Consulté le 9 février 2026.
Gansané A, Moriarty LF, Ménard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018. Malar J. 19 janv 2021;20(1):48. doi:10.1186/s12936-021-03585-6
Gansane A, Tarama, Lingani, Siaka Debe, Farida Tiendrebeogo, C, Moussa W.Efficacy_of_artemether_lumefantrine_dihydroartemisinin_piperaquine_and_artesunate_pyronaridine_for_the_treatment_of_uncomplicated_Plasmodium_falciparum_malaria_in_Burkina_Faso_2020_2021_b17a5d35cc.pdf. [En ligne] https://media.malariaworld.org/Efficacy_of_artemether_lumefantrine_dihydroartemisinin_piperaquine_and_artesunate_pyronaridine_for_the_treatment_of_uncomplicated_Plasmodium_falciparum_malaria_in_Burkina_Faso_2020_2021_b17a5d35cc.pdf. Consulté le 8 Juillet 2026.
Somé AF, Sorgho H, Zongo I, Bazié T, Nikiéma F, Sawadogo A, et al. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite. 2016; 23:60. doi:10.1051/parasite/2016069 PubMed PMID: 28004634; PubMed Central PMCID: PMC5178381.
Kojom Foko LP, Sharma A. Artemisinin resistance threat in Central and West Africa needs holistic action. J Public Health Afr. 16 janv 2026;17(1):1405. doi:10.4102/jphia. v17i1.1405 PubMed PMID: 41647602; PubMed Central PMCID: PMC12869459.
Maiga FO, Dembele L, Dama S, Diakite O, Diallo F, Sogore F, et al. Plasmodium falciparum field isolates drug susceptibility in Mali. JAC-Antimicrob Resist. 12 févr 2026;8(1): dlag015. doi:10.1093/jacamr/dlag015 PubMed PMID: 41696711; PubMed Central PMCID: PMC12895194.
Owoloye A, Olufemi M, Idowu ET, Oyebola KM. Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum. Malar J. 2 déc 2021; 20:451. doi:10.1186/s12936-021-03987-6 PubMed PMID: 34856982; PubMed Central PMCID: PMC8638531.
OMS. Combattre la résistance émergente aux médicaments antipaludiques en Afrique. nov 2022. [En ligne]. https://www.who.int/fr/news/item/18-11-2022-tackling-emerging-antimalarial-drug-resistance-in-africa. Consulté le 15 avril 2026]
Rapport OMS. World malaria report 2024. [En ligne]. https://www.who.int/fr/teams/global-malaria-programme/reports/world-malaria-report-2024. Consulté le 22 mai 2025.
Vestergaard LS, Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update
national malaria treatment policies. Am J Trop Med Hyg. déc 2007;77(6 Suppl):153‑9. PubMed PMID: 18165488.
Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, et al. Impact of Antimalarial Treatment and Chemoprevention on the Drug Sensitivity of Malaria Parasites Isolated from Ugandan Children. Antimicrob Agents Chemother. juin 2015;59(6):3018‑30. doi:10.1128/AAC.05141-14 PubMed PMID: 25753626; PubMed Central PMCID: PMC4432194.
Centre national de référence, Paludisme. CNR-Paludisme_rapport-2023_site-CNR.pdf.
Traoré A, Badolo A, Guelbeogo MW, Sanou A, Viana M, Nelli L, et al. Anopheline species composition and the 1014F-genotype in different ecological settings of Burkina Faso in relation to malaria transmission. Malar J. 8 mai 2019;18(1):165. doi:10.1186/s12936-019-2789-8
Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. N Engl J Med. 23 juin 2016;374(25):2453‑64. doi:10.1056/NEJMoa1513137
Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa. Nat Rev Microbiol. juin 2024;22(6):373‑84. doi:10.1038/s41579-024-01008-2 PubMed PMID: 38321292.
Duffey M, Shafer RW, Timm J, Burrows JN, Fotouhi N, Cockett M, et al. Combating antimicrobial resistance in malaria, HIV and tuberculosis. Nat Rev Drug Discov. juin 2024;23(6):461‑79. doi:10.1038/s41573-024-00933-4 PubMed PMID: 38750260; PubMed Central PMCID: PMC13042891.24. Rapport,OMS. world-malaria-report-2025-executive-summary-fre.pdf [En ligne]. https://cdn.who.int/media/docs/default-source/malaria/world-malaria-reports/world-malaria-report-2025-executive-summary-fre.pdf?sfvrsn=154ea8d5_26&download=true. Consulté le 31 déc 2025.
Awosolu OB, Yahaya ZS, Farah Haziqah MT. Prevalence, Parasite Density and Determinants of Falciparum Malaria Among Febrile Children in Some Peri-Urban Communities in Southwestern Nigeria: A Cross-Sectional Study. Infect Drug Resist. 2021; 14:3219‑32. doi:10.2147/IDR.S312519 PubMed PMID: 34434052; PubMed Central PMCID: PMC8380643.
Traoré K, Diakité SAS, Bah S, Konaté DS, Dabitao D, Sanogo I, et al. Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali. Drugs RD. 1 sept 2020;20(3):249‑55. doi:10.1007/s40268-020-00313-4
Tinto H, Bonkian LN, Nana LA, Yerbanga I, Lingani M, Kazienga A, et al. Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malar J. 31 mai 2014;13(1):207. doi:10.1186/1475-2875-13-207
Tahita MC, Tinto H, Yarga S, Kazienga A, Traore/Coulibaly M, Valea I, et al. Ex vivo anti-malarial drug susceptibility of Plasmodium falciparum isolates from pregnant women in an area of highly seasonal transmission in Burkina Faso. Malar J. 20 juin 2015; 14:251. doi:10.1186/s12936-015-0769-1 PubMed PMID: 26088768; PubMed Central PMCID: PMC4474342.
Mbaye A, Gaye A, Dieye B, Ndiaye YD, Bei AK, Affara M, et al. Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal. Malar J. 14 juin 2017; 16:250. doi:10.1186/s12936-017-1897-6 PubMed PMID: 28615016; PubMed Central PMCID: PMC5471902.
Bohissou FET, Nassa GJW, Sondo P, Rouamba T, Inoue J, Kaboré B, et al. Spatio-temporal trends of artemisinin-based combination therapy efficacy from 2010 to 2024 in sub-Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis. 25 nov 2025; 25:1684. doi:10.1186/s12879-025-12130-8 PubMed PMID: 41291512; PubMed Central PMCID: PMC12670823.
Coulibaly B, Pritsch M, Bountogo M, Meissner PE, Nebié E, Klose C, et al. Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. J Infect Dis. 1 mars 2015;211(5):689‑97. doi:10.1093/infdis/jiu540 PubMed PMID: 25267980.
Lingani M, Bonkian LN, Yerbanga I, Kazienga A, Valéa I, Sorgho H, et al. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malar J. 6 janv 2020; 19:8. doi:10.1186/s12936-019-3089-z PubMed PMID: 31906948; PubMed Central PMCID: PMC6945612.
Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. févr 2016;16(2):189‑98. doi:10.1016/S1473-3099(15)00318-7 PubMed PMID: 26601738; PubMed Central PMCID: PMC4726763.
da Silva C, Matias D, Dias B, Cancio B, Silva M, Viegas R, et al. Anti-malarial resistance in Mozambique: Absence of Plasmodium falciparum Kelch 13 (K13) propeller domain polymorphisms associated with resistance to artemisinins. Malar J. 19 mai 2023; 22:160. doi:10.1186/s12936-023-04589-0 PubMed PMID: 37208708; PubMed Central PMCID: PMC10199631.
Chidimatembue A, Svigel SS, Mayor A, Aíde P, Nhama A, Nhamussua L, et al. Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018. Malar J. 12 oct 2021; 20:398. doi:10.1186/s12936-021-03930-9 PubMed PMID: 34641867; PubMed Central PMCID: PMC8507114
Raman J, Mabona M, Nyawo Q, Mangena B, Kok G, Mathaba L, et al. Very low prevalence of validated kelch13 mutations and absence of hrp2/3 double gene deletions in South African malaria-eliminating districts (2022–2024). medRxiv. 1 avr 2025;2025.03.31.25324948. doi:10.1101/2025.03.31.25324948 PubMed PMID: 40236387; PubMed Central PMCID: PMC11998825.
Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602‑8doi:10.1038/s41591-020-1005-2 PubMed PMID: 32747827; PubMed Central PMCID: PMC7541349.
Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, et al. Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. N Engl J Med. 24 août 2023;389(8):722‑32. doi:10.1056/NEJMoa2211803 PubMed PMID: 37611122; PubMed Central PMCID: PMC10513755.
Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D, et al. Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine–pyrimethamine resistance in 13 regions in Tanzania in 2021: a cross-sectional survey. Lancet Microbe. oct 2024;5(10): None. doi:10.1016/S2666-5247(24)00160-5 PubMed PMID: 39159629; PubMed Central PMCID: PMC11464622.
Alemayehu AA, Castañeda Mogollón D, Belay SG, Tesfa H, Mohon AN, Balasingam N, et al. Expansion of the Plasmodium falciparum Kelch13 R622I Mutation in Northwest Ethiopia. Open Forum Infect Dis. 9 mai 2025;12(6): ofaf279. doi:10.1093/ofid/ofaf279 PubMed PMID: 40463829; PubMed Central PMCID: PMC12130971.
Martin AC, Sadler JM, Simkin A, Musonda M, Katowa B, Matoba J, et al. Emergence and Rising Prevalence of Artemisinin Partial Resistance Marker Kelch13 P441L in a Low Malaria Transmission Setting in Southern Zambia. medRxiv. 2 janv 2025;2025.01.02.24319706. doi:10.1101/2025.01.02.24319706 PubMed PMID: 39802768; PubMed Central PMCID: PMC11722444.
Agaba BB, Travis J, Smith D, Rugera SP, Zalwango MG, Opigo J, et al. Emerging threat of artemisinin partial resistance markers (pfk13 mutations) in Plasmodium falciparum parasite populations in multiple geographical locations in high transmission regions of Uganda. Malar J. 5 nov 2024; 23:330. doi:10.1186/s12936-024-05158-9 PubMed PMID: 39501325; PubMed Central PMCID: PMC11539793.
Kegya AD, Oppong E, Darko E, Boateng KA, Phillips RO, Heinemann M, et al. Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023. Trop Med Int Health TM IH. janv 2026;31(1):43‑8.doi:10.1111/tmi.70048 PubMed PMID: 41094545; PubMed Central PMCID: PMC12775893.
Wakoli DM, Ondigo BN, Ochora DO, Amwoma JG, Okore W, Mwakio EW, et al. Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs. BMC Med. 18 nov 2022; 20:448. doi:10.1186/s12916-022-02652-2 PubMed PMID: 36397090; PubMed Central PMCID: PMC9673313.
Rosado J, Fola AA, Cojean S, Sarrasin V, Coppée R, Bailly J, et al. Assessment of ex vivo antimalarial drug efficacy in African Plasmodium falciparum parasite isolates, 2016–2023: a genotype–phenotype association study. eBioMedicine. 1 août 2025 ;118 :105835. doi: 10.1016/j.ebiom.2025.105835
Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, et al. In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. Malar J. 25 nov 2013; 12:431. doi:10.1186/1475-2875-12-431 PubMed PMID: 24274185; PubMed Central PMCID: PMC4225597.
Chaorattanakawee S, Lon C, Jongsakul K, Gawee J, Sok S, Sundrakes S, et al. Ex vivo piperaquine resistance developed rapidly in Plasmodium falciparum isolates in northern Cambodia compared to Thailand. Malar J. 21 oct 2016; 15:519. doi:10.1186/s12936-016-1569-y PubMed PMID: 27769299; PubMed Central PMCID: PMC5075182.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sciences de la Santé
This work is licensed under a Creative Commons Attribution 4.0 International License.
